234 related articles for article (PubMed ID: 12558776)
1. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
2. Virus removal capacity at varying ionic strength during nanofiltration of AlphaNine® SD.
Jorba N; Shitanishi KT; Winkler CJ; Herring SW
Biologicals; 2014 Sep; 42(5):290-3. PubMed ID: 24999080
[TBL] [Abstract][Full Text] [Related]
3. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
4. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
5. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
6. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
7. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
8. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
9. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
10. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
11. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
13. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
Klamroth R; Gröner A; Simon TL
Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
[TBL] [Abstract][Full Text] [Related]
14. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
15. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
16. [Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality].
Römisch J; Gröner A; Bernhardt D; Diehl KH; Hein B; List W; Müller HG; Nowak T; Ronneberger H; Schüler E; Weimer T; Hilfenhaus J
Beitr Infusionsther Transfusionsmed; 1996; 33():220-4. PubMed ID: 8974698
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
18. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
20. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
Koenderman AH; ter Hart HG; Prins-de Nijs IM; Bloem J; Stoffers S; Kempers A; Derksen GJ; Al B; Dekker L; Over J
Biologicals; 2012 Nov; 40(6):473-81. PubMed ID: 22901944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
